140 results about "Antihypertensive medicines" patented technology

Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, mild cognitive impairment, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability, and a therapeutic agent selected from the group consisting of anti-Alzheimer's agents, anti-diabetic agents, agents capable of increasing utilization of lipids, anti-atherosclerotic agents, anti-hypertensive agents, anti-inflammatory agents, anti-obesity agents, and combinations thereof. Preferred therapeutic agents include donepezil, rivastigmine, galantamine, and memantine.

Compounds are disclosed having the formulae: wherein R' is hydrogen, lower alkyl or lower alkoxy; r is 0 or 1 and p is zero to four; and wherein R1 is selected from the group, consisting of radicals represented by the general formulae: wherein Y is selected from the group consisting of lower alkyl, lower alkoxy, and halogen; Z is oxygen, sulfur or -NH, Q is -CH or nitrogen; a is zero or an integer of from one to three; and wherein, R2 is selected from the group consisting of hydrogen and straight chain, branched and cyclic hydrocarbyl radicals having from one to four carbon atoms, and optionally substituted with a hydroxyl radical; and wherein X is two hydrogen atoms or oxygen and B is selected from oxygen and nitrogen, and pharmaceutically acceptable salts thereof, with the proviso that when X is two hydrogen atoms, B is oxygen, and with the further proviso that when B is oxygen then R1 cannot be a phenyl or a substituted phenyl radical. Pharmaceutical preparations using these compounds and a method for inducing an adenosine response mediated by the adenosine A2 receptor by administering these compounds are also disclosed.

The present invention relates to the preparation of Timisatan as one active component for antihypertensive medicine. The carboxylic ester derivative is first obtained through the nucleophilic substitution reaction between some intermediate and 4'-bromomethyl biphenyly-2-carboxylic ester, and then hydrolyzed to eliminnate protection radical and to obtain the destination product. In the technological process of the present invention, methyl radical and ethyl radical are used as protecting radical, and this facilitates and stabilizes the preparation of 4'-bromomethyl biphenylyl-2-methyl carboxylic ester and 4'-bromomethyl biphenylyl-2-ethyl carboxylic ester, and results in easy to control reaction with the intermediate, less impurity, easy elimination of protecting radical and high product yield and quality.

A depressor peptide with higher suppression activity to angiotensin-converting enzyme (ACE) and having 6 amino acids is prepared from the protein of Chinese shrimp through enzymolyzing, separation and purifying. Its short peptide with 12 sequences is chemically synthesized. It can be used to prepare antihypertensive medicine.

The present invention generally concerns the management of age-related diseases in domestic animals. Specifically, the present invention is directed to combination therapies for the treatment of progressive renal diseases (e.g., Chronic Renal Failure) and their accompanying secondary disease states. In a composition aspect, the present invention provides a composition comprising a phosphate binder and another pharmaceutically active ingredient. The other pharmaceutically active ingredient is selected from a group consisting of antihypertensives, calcitrol, vitamin D analogues, lipid restriction products, potassium salts, treatments for anemia and alkalization compounds.

A composite medicine for improving the curative effect of the antihypertensive medicine containing Ca channel retardant and preventing the complications such as eyeground hemorrhage, angina pectoris, myocardial infarction, cerebral apoplexy, heart failure and kidney failure is composed of Ca channel vetardant or its precursor or its active metabolite or its salt, one or more of vitamins in B family and the pharmacologically acceptable carrier.

The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1–36). As a consequence of the resulting enhanced stability of the endogenous NPY (1–36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating anti-depressive, anxiolytic, analgesic, anti-hypertension and other neurological effects.

The invention provides a valsartan compound and a new manufacturing method thereof. In the invention, through specially designed methods for acid and alkali conversion and absorption by macroporous absorption resin, the aim of refining and purifying can be fulfilled; and thus, the high-purity valsartan compound is obtained, the product quality of the preparation is improved, the toxic and side effects are reduced, and the clinic medicine safety of the valsartan in the preparation of antihypertensive medicines is guaranteed.

The invention discloses a compound apigenin nanoemulsion antihypertensive drug which comprises the following raw materials in mass percent: 1-15% of apigenin, 5-35% of surfactant, 1-20% of cosurfactant, 1-20% of oil, 0.5-10% of motherwort fruit aqueous extract, 0.5-10% of semen cassiae water extract and the balance of distilled water; and the sum of mass percents of the above raw materials is 100%. The nanoemulsion is small in emulsion droplet, uniform in distribution, low in viscosity and good in liquidity. After apigenin is prepared into a nanoemulsion, blood brain barrier transmission capacity is obviously increased, the bioavailability of a technical material is obviously improved, the half-life period of the drug can be prolonged; and the drug administration times can be reduced; with adoption of the nanoemulsion, the dissolution and infiltration capacity of atenolol can be improved and the stability of apigenin is increased; and the nanoemulsion has obvious synergistic effect compounded with the motherwort fruit and the semen cassiae; and the medicinal cure effect can be more fully played.

The present invention relates to pharmaceutical compositions for reducing essential hypertension and systemic inflammation. While many drugs have been found to treat hypertension, the currently available drugs often do not maintain reduced blood pressure at the preferred norm of 115 / 75 mm Hg or less throughout a 24 hour period. The current invention provides compositions comprising at least one hypertensive drug combined with the natural product Coenzyme Q10 (ubiquinone or CoQ10), which synergizes with the antihypertensive drugs to maintain low blood pressure throughout the day and night while generating other positive effects on the risks of cardiovascular disease, renal failure, and stroke. CoQ10 also counteracts some of the side effects of some hypertensive drugs such as tiredness, weakness, and / or liver toxicity. The invention further describes therapeutically effective methods for reducing systemic inflammation in hypertensive mammals comprising treatment with an antihypertensive composition that includes at least one angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and CoQ10 (ubiquinone). The invention metrics for reducing systemic inflammation comprise the reduction of serum levels of high sensitivity C-reactive protein (CRP), Interleukin 6 (IL-6), and / or tumor necrosis factor-alpha (TNF-alpha). These antihypertensive-CoQ10 combinations will synergistically reduce both hypertension and systemic inflammation.

A blood pressure self-monitoring device includes an alarm generator to remind the patient to carry out blood pressure measurements according to a predetermined schedule. The device performs a specific phase of measuring blood pressure according to a clinically validated criterion, and calculates an accurate blood pressure reading on the basis of plural measurement values. The device also has a therapeutic decision mode, which can monitor blood pressure for assessing the effect of antihypertensive drug treatment. In the extended mode, the alarm generator works according to a predetermined daily measurement to remind the patient to take a blood pressure measurement following drug intake. Also during the treatment phase, the antihypertensive drug may affect the probability of irregular heartbeat, which can be a reference index for assessing the types and doses of treated antihypertensive drug. The device can also use a selectable switch to operate as a regular home blood pressure monitor.

The invention discloses polypeptide of Phascolosoma esculenta which is a polypeptide segment prepared through hydrolysis of extracted protein of the Phascolosoma esculenta. The protein of the Phascolosoma esculenta comprises water-soluble protein, waterinsoluble protein and a mixture thereof. The hydrolysis method comprises protease hydrolysis, acid hydrolysis and alkali hydrolysis. The polypeptide of the Phascolosoma esculenta can be used for inhibiting angiotensin converting enzyme (ACE), so the polypeptide can be used for preparing antihypertensive medicines, and a new way for effectively utilizing the Phascolosoma esculenta is opened up.

The invention relates to antihypertensive nutritional health-care rice and a making method thereof. The antihypertensive nutritional health-care rice comprises rice, red pearl rice, shelled buckwheat, shelled oatmeal, small red bean, fructus lycii, hawthorn and carrot dices. The making method of the antihypertensive nutritional health-care rice includes the steps of soaking and drying the materials, and adding water to boil to obtain the antihypertensive nutritional health-care rice. The antihypertensive nutritional health-care rice is reasonable in proportion, nutritional, scientific, and rich in nutrients necessary to human bodies. The rice can be boiled with a ceramic pot into boiled rice, which is fragrant and attractive in color, has the effects of heat clearing, detoxication, blood lipid lowering, spleen tonifying, stomach invigorating, liver nourishing and blood pressure lowering, and has dietary and health-care functions.

The present invention relates to a planar-shaped drug preparation that quickly dissolves or decomposes in an aqueous environment, for the application of active ingredient combinations for the treatment of hypertension, wherein the drug preparations contain at least two active ingredients that are suitable for the treatment of hypertension, and wherein the antihypertensive drug is selected from the group that encompasses beta receptor blockers, alpha receptor blockers, calcium antagonists, ACE inhibitors, AT1 antagonists, centrally acting antihypertensive drugs, direct vasodilators, and diuretics. The present invention also relates to the use of active ingredient combinations according to the invention for the production of an oral drug preparation for the treatment of high blood pressure, to a method for the therapeutic treatment of hypertension, and to a method for the production of a planar-shaped drug preparation.

Methods and therapeutic combinations are provided for lowering blood pressure in a subject exhibiting resistance to a baseline antihypertensive therapy with one or more drugs, or a subject having diabetes and / or chronic kidney disease. A method of the invention comprises administering, in some embodiments adjunctively with a modified baseline therapy, a compound of formula (I) as defined herein. A therapeutic combination of the invention comprises a compound of formula (I); at least one diuretic; and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers; wherein the at least one diuretic and / or the at least one antihypertensive drug are present at substantially less than a full dose.

The invention relates to an antihypertensive medicine which is characterized by be prepared from the following raw materials in parts by weight: 20-30 parts of uncaria rhynchophylla, 20-30 parts of concha haliotidis, 15-20 parts of white paeony roots, 15-30 parts of roots of kudzu vine, 15-30 parts of selfheal, 9-15 parts of scutellaria baicalensis, 10-15 parts of chrysanthemum, 10-15 parts of ligusticum wallichii, 10-15 parts of loranthus parasiticus, 10-15 parts of gastrodia elata, 5-10 parts of poria cocos, 5-10 parts of white atractylodes rhizome and 10-20 parts of lumbricus. The antihypertensive medicine has a good effect and has no side effects.

A composite medicine for treating hypertension contains proportionally one or two antihypertensive medicines chosen from calcium antagon, alpha receptor blocker, beta receptor blocker, renin-angiotonin system regulator and diuretic, one Ca containing component and the farmacologically acceptable auxiliary.

The present invention provides a an angiotensin receptor antagonist and creatine phosphate sodium complex and uses thereof, wherein the complex comprises an angiotensin receptor antagonist and creatine phosphate sodium, a molar ratio of the angiotensin receptor antagonist to the creatine phosphate sodium is 1:1-2, and the angiotensin receptor antagonist is selected from valsartan, losartan, irbesartan, telmisartan, eprosartan, candesartan, olmesartan, saprisartan, tasosartan, and elisartan. According to the present invention, the complex is formed by compounding the angiotensin receptor antagonist and the creatine phosphate sodium, and provides the unexpected double effect and the synergistic effect for treatment of heart failure and high blood pressure, the cocrystallization salt hydrate formed by linking the hydrogen bond has the stable characteristic, the pharmacokinetic property is significantly provided, and the positive application prospects are provided in the fields of anti-high blood pressure treatment and anti-heart failure treatment.

The invention relates to a pharmaceutical composition containing azilsartan. The pharmaceutical composition particularly comprises azilsartan and at least one other antihypertensive medicine. The collaborative antihypertensive effect can be effectively played. The pharmaceutical composition for lowering blood pressure, which has a good antihypertensive effect, stable pressure reduction, and good tolerance, is provided.

Modified or extended release formulations containing propanolol compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved propanolol formulations such as INDERAL LA®.

Disclosed is a novel fused bicyclic compound [I] shown below, which has affinity for a mineralcorticoid receptor (MR) and is useful as an anti-hypertensive agent or the like. Specifically disclosed is a compound represented by the formula [I] or a pharmacologically acceptable salt thereof. [I] wherein the ring A represents a benzene ring which is fused with the adjacent heterocyclic 6-membered ring and has a substituent R1, and which may have a substituent other than R1; R1 represents an alkylsulfonylamino group or the like; R2 and R3 (a) independently represent a hydrogen, an alkyl or a substituted or unsubstituted aryl, (b) together form an oxo, or (c) together with the adjacent carbon atom, form a cycloalkyl; X represents =N-, =C(R4)- or -CH(R4)-; R4 represents (a) a hydrogen, (b) a cyano, (c) a halogen, (d) an alkyl, (e) an alkenyl, (f) a cycloalkyl, (g) an alkanoyl, (h) a carbamoyl or (i) a cycloalkenyl; Ar represents a substituted or unsubstituted aromatic cyclic group; and a dotted line means the presence or absence of a double bond.

An antihypertensive drug cilazapril intermediate is the compound of the structural formula 1, which is obtained by the steps of alkalising the compound of structural formula 2 to remove L-tartaric acid and obtaining the compound of structural formula 3, subjecting the compound of structural formula 3 and the compound of structural formula 4 to a reaction to obtain a single SS-configuration compound 1 of structural formula 1. The compound of structural formula 1 in the invention is cyclized to obtain the compound of structural formula 8. The compound of structural formula 8 is processed by reduction through borane, protective group removal and suprafacial chain condensation, and is processed by tertiary butyl protective group removal under the action of hydrochloric acid gas so as to obtainthe antihypertensive drug cilazapril 13. The invention uses front split, obtains a single SS-configuration new compound of structural formula 1, avoids column-passing spit in subsequent procedures, s implifies synthesis technology, decreases cost, and reduces three wastes. Thus, the invention is more suitable for commercial production.

The present invention relates to sustained release solid pharmaceutical composition comprising antihypertensives, in particular, Metoprolol succinate or pharmaceutically acceptable derivatives thereof and a process for preparing such a formulation. The present invention is a composition comprising Metoprolol succinate or its pharmaceutically acceptable derivatives thereof and the composition releases the drug over 24 hours. The composition further comprises hydrophilic polymer matrix based tablets. The present invention describes a sustained release tablet comprising sustained release matrix comprising of gelling agents comprising at least one hydrophilic polymer with one or more gum and gum derivatives.

The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-4 (DPP-4) inhibitor and an anti-hypertensive agent selected from the group consisting of an angiotensin II receptor antag-onist and an angiotensin converting enzyme inhibitor, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes-related disorders, hypertension, and hypertension-related disorders.

The invention discloses a compound oral preparation and a preparation method thereof. The compound oral preparation is used for treatment of high blood pressure and has significant effect. The preparation includes three anti-hypertensive drugs hydrochlorothiazide, amlodipine besylate, valsartan and pharmaceutical excipients. The three components all belong to hydrophobic drugs, so that the dissolution rate is one of the key indicators measuring the intrinsic quality of the preparation. A specific ratio of the raw materials to the excipients is adopted by the invention, especially a polyoxyethylene-polyoxypropylene copolymer is used, for instance poloxamer serves as a solubilizing agent, so that compared with the anti-hypertensive compound preparation EXFORGE HCT produced by American Novartis pharmaceutical company, the compound preparation has good similarity in terms of dissolution behavior. According to the invention, wet granulation or dry granulation is employed to effectively solve the problems of low bulk density, poor liquidity, strong moisture absorption, and sticking and picking of Valsartan. The preparation method of the compound preparation is simple and practical, and the product has stable quality, and good dissolution rate and content uniformity of each effective component, thus being suitable for large-scale industrial production.

The invention relates to a synthesis method for preparing an antihypertensive medicine having a benzofuroxan ring. In the method, 4-methylbenzofuroxan is used as a raw material, the 2,1,3-benzoxadiazole-4-aldehyde serving as an important intermediate is prepared by bromination and oxidation reactions, and the 2,1,3-benzoxadiazole-4-aldehyde and acetoacetic ester undergo a Hantzsch reaction to form the target compound. Compared with other processes, the method has the characteristics of mild reaction conditions, simple and efficient operation, high yield and the like and has a certain industrial production prospect.

Modified or extended release formulations containing propanolol compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved propanolol formulations such as INDERAL LA®.

This invention provides therapeutic compositions of cicletanine and other furopyridines for the treatment of, elevated pulse pressure or isolated systolic hypertension, as well as general hypertension, in monotherapy and in combined therapy with other anti-hypertensive agents (such as organic and inorganic nitrogen donors, calcium channel blockers, diuretics, beta blockers, angiotensin receptor blockers, ACE inhibitors, aldosterone antagonists, renin inhibitors and centrally-acting antihypertensives) cardiovascular agents (such as medications to treat heart failure) and oral antidiabetic agents (such as biguanides and glitazones). Such compositions include enantiomerically pure (positive or negative) embodiments, as well as enantiomeric mixtures other than a racemic mixture, and include daily dosages of less than 50 mg. Further provided are methods of treatment of general or systolic hypertension, wherein patients are administered the inventive compositions, either a monotherapeutic furopyridine composition, or a combination therapy, which includes a second agent in addition to the furopyridine, for treatment of general hypertension or systolic hypertension, and hypertension-associated complications.

The invention discloses an antihypertensive royal jelly composition. The antihypertensive royal jelly composition is prepared from the following raw materials in parts by weight: 60 to 80 parts of royal jelly, 35 to 48 parts of honey, 5 to 10 parts of bee pollen, 20 to 35 parts of emulsifiers, 3 to 12 parts of glycerinum, 10 to 18 parts of tea polyphenol, 5 to 8 parts of lycopene, 5 to 10 parts of rock candies, 1.2 to 3.5 parts of lucid ganoderma, 5 to 8 parts of radix puerariae, 2.3 to 5.8 parts of harlequin glorybower leaves, 1 to 8 parts of uncaria rhynchophylla, 1 to 9 parts of prunella vulgaris, 10 to 20 parts of wild chrysanthemum flowers, 5 to 10 parts of semen cassia, 3 to 9 parts of cattail pollen and 2 to 7 parts of rhizoma alismatis. The antihypertensive royal jelly composition is reasonable in composition proportion, complete and rich in nutrients, high in content of active ingredients, free from additives by adopting the pure natural traditional Chinese medicine formula, non-toxic, free from side effect on the human body, capable of being eaten for a long time, and remarkable in antihypertensive effect.